Meeting
2014 ASCO Annual Meeting
Patterns of tumor progression in a phase 3 study of bevacizumab (Bv) plus radiotherapy (RT) plus temozolomide (T) for newly diagnosed glioblastoma (GB).
Authors
Wolfgang Wick
Neurooncology, University of Heidelberg Medical Center, Heidelberg, Germany
Wolfgang Wick , Olivier L. Chinot , Warren P. Mason , Roger Henriksson , Frank Saran , Ryo Nishikawa , Cedric Revil , Yannick Kerloeguen , Timothy Francis Cloughesy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00943826
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2051^)
DOI
10.1200/jco.2014.32.15_suppl.2051
Abstract #
2051^
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio).
First Author: Martha Nowosielski
Poster
2013 ASCO Annual Meeting
Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM).
First Author: Ryo Nishikawa
Poster
2011 ASCO Annual Meeting
AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
First Author: O. L. Chinot
Poster
2020 ASCO Virtual Scientific Program
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.
First Author: Wenyin Shi